Navigation Links
Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
Date:2/25/2008

Harris Expands Enterprise Intelligence Systems to Healthcare Market

ORLANDO, Fla., Feb. 25 /PRNewswire-FirstCall/ -- HIMSS, Booth #1841 -- Harris Corporation (NYSE: HRS), an international communications and information technology company, has joined forces with Cancer Treatment Services International (CTSI) to advance the quality and delivery of radiation oncology. Harris will provide advanced imaging and information systems that assure critical medical information is delivered with accuracy, speed, security and privacy.

"We believe Harris' expertise in image processing and enterprise intelligence will significantly advance radiation oncology," said Dr. Jeff Shogan, MD and chairman of CTSI. "Our collaboration with Harris will enhance our ability to deliver the highest quality cancer treatment services to more people, more effectively."

"We are very pleased to be working with CTSI and Dr. Shogan, who is a leading practitioner and innovator in cancer treatment services on an international scale," said Jim Traficant, vice president of Harris Healthcare Solutions. "We have been working closely with Dr. Shogan to leverage our imaging and informatics expertise to deliver enterprise intelligence to radiation oncology."

CTSI L.P. is a provider of comprehensive treatment for cancer patients with a main focus on medical oncology and radiation oncology. The company was founded by a core group of physicians and businessmen with substantial experience in the development, operation and networking of cancer services on a national and international level. CTSI is able to provide innovative and technologically-advanced treatment solutions to areas of the world where therapy is currently inadequate in either quality or capacity.
'/>"/>

SOURCE Harris Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...., Oct. 7 /- A study published in the...m cell self-renewal,reported that InVitria,s ( ht...an serum albumin) was an effective replacement to ...icle entitled, "The ground state of embryonic stem...ed Cellastim as a recombinant,albumin in place of ...
(Date:10/7/2008)...Oct. 7 /- Aerovance Inc. today report...se I trial of its Aerovant,inhalation powder that ...local irritancy following asthma patients, inhalat... be the highest of three doses investigated in,Aer...heduled to begin early,next year. Evidence gathere...
(Date:10/7/2008).../- Ardea Biosciences, Inc.,...itled "RDEA119, a Potent,and Highly Selective MEK1...um (DSS) -- induced Chronic Colitis in Mice," was ...ogy (ACG) 2008 Annual Meeting in Orlando,Florida....l study of,RDEA119, the Company,s lead mitogen-act...
(Date:10/7/2008)...k, October 7 /-, - 125 Pat...ase II Study,Shows Statistically Significant Impro...luated the mature phase II data from the,therapeut...that had been,obtained as part of the recently ent...e (NCI) in the US., The results from the Phase II...
Breaking Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 1Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 2Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 3Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 4Brain Slow to Judge Fast Moving Objects Head On 25082 1Brain Slow to Judge Fast Moving Objects Head On 25082 2Autistic Children Make Limited Eye Contact 25080 1Autistic Children Make Limited Eye Contact 25080 2Autistic Children Make Limited Eye Contact 25080 3AUDIO from Medialink and BP 3A Younger for Longer 25078 1
...007 - CeNeS Pharmaceuticals (AIM:CEN),("CeNeS" or ...al,company today announced that a paper published ...othesis that a,catechol-O-methyltransferase (COMT)...l agent to address profound cognitive,deficits in ...ngoing discovery programme to develop novel COMT i...
...at Eight Weeks Sustained up to 12 Weeks,and Drug R... Calif., July 02, 2007,/PRNewswire-FirstCall/ -- A...rm, follow-up results from a Phase 2 study showing...5) in patients with,moderate-to-severe osteoarthri... pain that persisted for up to 12 weeks. , "The po...
Other Medicine Technology:Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 2Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 3Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 2Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 3Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 5
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...Infirmary in Scotland will be the first in United ...eration in recipient. The Health Minister Andy Ker...ld be done followed by ten the next year//. In li...f liver is transplanted and regenerated following ...
Canadians flocking to India for quick and efficient medical treatment
...ab) drug is found to be useful in treating patient...by the European Medicines Agency (EMEA) for use in...rent drugs//. Xolair can be used in the treatment ...ffects of the new drug on long time usage has to b...
...suggests that the melanocortin system is an import...l neuronal plasticity observed after chronic morph...is accompanied by the development of morphine tole...s associated with opiate treatment. Possible modul...
Other Medicine News:Health News:Inhibition of morphine tolerance by spinal melanocortin receptor blockade 2
Cholesterol/HDL Standard 50 mg/dl.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
Medicine Products: